International Assets Investment Management LLC Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

International Assets Investment Management LLC acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 18,108 shares of the company’s stock, valued at approximately $1,800,000.

Other hedge funds have also recently bought and sold shares of the company. Hudson Bay Capital Management LP increased its stake in shares of Vir Biotechnology by 1,975.0% in the third quarter. Hudson Bay Capital Management LP now owns 207,500 shares of the company’s stock valued at $1,944,000 after buying an additional 197,500 shares in the last quarter. Barclays PLC increased its stake in shares of Vir Biotechnology by 124.6% in the third quarter. Barclays PLC now owns 412,161 shares of the company’s stock valued at $3,863,000 after buying an additional 228,634 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Vir Biotechnology by 205.5% in the third quarter. State of Alaska Department of Revenue now owns 153,494 shares of the company’s stock valued at $1,438,000 after buying an additional 103,246 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its stake in shares of Vir Biotechnology by 582.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 162,128 shares of the company’s stock valued at $1,519,000 after buying an additional 138,387 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Vir Biotechnology in the third quarter valued at $1,098,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vir Biotechnology news, CEO Backer Marianne De sold 72,995 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total transaction of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares in the company, valued at $6,418,203.22. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Ann M. Hanly sold 2,711 shares of Vir Biotechnology stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $10.05, for a total transaction of $27,245.55. Following the transaction, the executive vice president now owns 132,069 shares in the company, valued at approximately $1,327,293.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Backer Marianne De sold 72,995 shares of Vir Biotechnology stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares in the company, valued at approximately $6,418,203.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,831 shares of company stock worth $1,525,844. Insiders own 18.10% of the company’s stock.

Vir Biotechnology Stock Down 0.1 %

Vir Biotechnology stock opened at $7.95 on Friday. The business’s 50-day simple moving average is $10.12 and its 200 day simple moving average is $9.62. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -1.73 and a beta of 0.41. Vir Biotechnology, Inc. has a 12-month low of $7.72 and a 12-month high of $27.48.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.28. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The firm had revenue of $16.80 million for the quarter, compared to analysts’ expectations of $11.18 million. During the same quarter last year, the business earned ($0.76) earnings per share. The company’s revenue was down 66.0% compared to the same quarter last year. As a group, sell-side analysts expect that Vir Biotechnology, Inc. will post -4.04 EPS for the current year.

Analyst Upgrades and Downgrades

VIR has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, March 15th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.